A5008138752- CAR-T cell therapy research
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- COVID-19 Clinical Research Studies
University of Southern California
2024
Novartis (United States)
2022
T cell receptor (TCR)-engineered therapy is a promising potential treatment for solid tumors, with preliminary efficacy demonstrated in clinical trials. However, obtaining clinically effective TCR molecules remains major challenge. We have developed strategy cloning tumor-specific TCRs from long-term surviving patients who responded to immunotherapy. Here, we report the identification of (10F04), which human leukocyte antigen (HLA)-DRA/DRB1*09:01 restricted and papillomavirus type 18 (HPV18) E7
Background: New therapies for multiple myeloma (MM) such as immunomodulatory drugs (IMiD), proteasome inhibitors (PI), and CD38-targeted monoclonal antibodies (anti-CD38 mAb) enhance the overall survival (OS) of patients (pts) with relapsed and/or refractory (r/r) MM. However, MM remains incurable, insufficient rates duration response, progression-free (PFS). B-cell maturation antigen (BCMA) is expressed in cells essential maintenance long-lived plasma cells. It a clinically validated target...